JPS5875558A - Mountable artificial kidney - Google Patents
Mountable artificial kidneyInfo
- Publication number
- JPS5875558A JPS5875558A JP56173716A JP17371681A JPS5875558A JP S5875558 A JPS5875558 A JP S5875558A JP 56173716 A JP56173716 A JP 56173716A JP 17371681 A JP17371681 A JP 17371681A JP S5875558 A JPS5875558 A JP S5875558A
- Authority
- JP
- Japan
- Prior art keywords
- artificial kidney
- blood
- kidney
- hemodialysis
- dialysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は、装着型人工腎臓装置に関するものであり、詳
しくは昼間は血液濾過、夜間就寝中は血液透析を行なう
ことにより、腎不全患者の昼間に於ける社会活動を可能
とならしめることを目的とするものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a wearable artificial kidney device, and more specifically, by performing hemofiltration during the day and hemodialysis during the night while sleeping, the present invention allows renal failure patients to perform social activities during the day. The purpose is to make it possible.
慢性腎不全、尿毒症等の腎疾患により、排尿機能が無く
なるか、或いは著るしく低下した患者に対して、人工腎
臓による血液透析、生体の腹膜の透過作用を利用した腹
膜透析、或いは多量の体液を交換する血液−過等の血液
浄化法により治療が行な゛われている。これらの血液浄
化法は、尿素尿酸、クレアチニン等の老廃物の除去、N
&、x%at、 O&、’g、Po4ep(D体内電解
質の調整、酸塩基平衡の調整及び生体内に過剰に蓄積さ
れる水分の除去等を行ない、生体腎機能6時間の血液透
析、或いは血液濾過を受ける故、通院による時間制約の
ため日常の社会活動に大きく支障をきたしている。この
社会復帰を少しでも可能ならしめる方法として、夜間透
析や家庭透析も一部行なわれているが、医師、透析スタ
ッフ岬の確保難、経済面での出費増、安全面等で問題が
多い。For patients whose urinary function has been lost or has significantly decreased due to renal diseases such as chronic renal failure or uremia, hemodialysis using an artificial kidney, peritoneal dialysis using the permeability of the living body's peritoneum, or high-dose treatment. Treatment is by blood purification methods such as blood purification, which involves exchanging body fluids. These blood purification methods include the removal of waste products such as urea uric acid and creatinine, and the removal of N
&, x%at, O&,'g, Po4ep (D Adjustment of electrolytes in the body, adjustment of acid-base balance, and removal of water excessively accumulated in the body, etc., and 6-hour hemodialysis to improve biological kidney function, or As patients undergo hemofiltration, the time constraints of hospital visits greatly hinder their daily social activities.Sometimes night dialysis and home dialysis are performed as a way to make this return to society as possible as possible. There are many problems such as difficulty in securing doctors and dialysis staff, increased financial expenses, and safety.
また、週2〜3回の血液透析或いは血液濾過は、生体腎
が昼間であれ夜間であり常時機能しているのに比し、壕
とめて行危う、つ壕b1血液の浄化ス2−ドで表現する
なら10〜20倍も早い速度で急激に水分除去や老廃物
の除去を行なう故、不均衡症候群、血圧変動等の合併症
が多発する原因である。しかも食事面で本水分、食塩の
摂取量も極端表制限をしなければならず、患者にとって
は大きな苦痛の一つでもある。血液透析或いは血液濾過
の回数を増やせば、前述の合併症の発症や食事面での制
限も緩和できるが、通院回数の増加による時間制約、ベ
ッド数″−’−)
□不足、医師、透析スタッフ等の増加、経費増勢の面で
、実現が非常に困難と考えられる。In addition, hemodialysis or hemofiltration performed two or three times a week is a difficult task, as compared to the biological kidneys, which function constantly during the day and night. In other words, the rapid removal of water and waste products at a rate 10 to 20 times faster is the cause of frequent complications such as imbalance syndrome and blood pressure fluctuations. Moreover, in terms of diet, the intake of water and salt must be extremely limited, which is a major pain for patients. If the frequency of hemodialysis or hemofiltration is increased, the aforementioned complications and dietary restrictions can be alleviated, but time constraints due to the increased number of hospital visits, number of beds ″−'−) □Insufficient doctors, dialysis staff This is considered to be extremely difficult to achieve due to the increase in costs and expenses.
一方装置面では、血液透析、血液濾過、腹膜透析等の血
液浄化療法には、血液透析器或いは血液濾過器、血液4
ンゾ、シャント血液回路、透析液供給装置、ヘノリン注
入装童、輸液勢の補充液供給装置、監視装−等各種用具
、装置類を用いて、血液浄化装置を構成するが、従来の
血液浄化装置は、どの療法も装置が大きく、血液透析装
置の場合は多量に透析液を使用するし、血液濾過の場合
には約2ntの補充液を要し、またいずれの血液浄化方
法も、抗凝血剤であるヘノ譬リンを注入するポンプが不
可欠であり、装置を主とするシステムの小型化、極小化
が極めて困難であり、これらのシステムを装着し、日常
活動を行なうことは不可能に近い。On the other hand, in terms of equipment, blood purification treatments such as hemodialysis, hemofiltration, and peritoneal dialysis require hemodialyzers, hemofilters, and blood
A blood purification device is constructed using various tools and devices such as a tube, a shunt blood circuit, a dialysate supply device, a henolin infusion device, an infusion fluid supply device, and a monitoring device. The devices used for all therapies are large; hemodialysis machines use a large amount of dialysate; hemofiltration requires approximately 2 nt of replenishment fluid; and all blood purification methods require anticoagulants. Pumps for injecting the blood agent Henomanrin are essential, and it is extremely difficult to miniaturize and miniaturize systems based on devices, making it impossible to carry out daily activities while wearing these systems. close.
以上述べた如く、従来の通院による血液浄化法、夜間透
析、家庭透析或いは装着方式は、いずれも患者が健康人
に近いレベルでの日常生活を行なう、所謂社会復帰を可
能とするには解決)すべき困難な問題を有していた。As mentioned above, conventional outpatient blood purification methods, night dialysis, home dialysis, and wearing methods are all solutions to enabling patients to return to society, where they can carry out their daily lives at a level close to that of a healthy person. I had a difficult problem to solve.
本発明者等は、かかる問題点を解決すべく鋭意検討し九
結果、患者の社会復帰を可能とする本発明の装着型人工
腎臓を構成した。以下本発明について詳述する。The present inventors have made extensive studies to solve these problems, and as a result, have constructed the wearable artificial kidney of the present invention, which enables patients to return to society. The present invention will be explained in detail below.
本発明者等は、装着型人工腎臓の構成要件として、昼間
の社会活動時には血液濾過を行ない、夜間就寝中は血液
透析を行なう事を前提として、極小化且つ軽量化を図り
得る実現可能な装着型人工腎臓を提供せんがために、次
の事項を達成すべく検討を進めた。The present inventors have developed a wearable artificial kidney that can be miniaturized and lightweight, assuming that the wearable artificial kidney will perform hemofiltration during social activities during the day and perform hemodialysis during sleep at night. In order to provide a type of artificial kidney, we proceeded with the study to achieve the following items.
(1)生体腎の除水スピードに近い人工腎臓、(2)血
液ポンプを必要としない人工腎臓、(3)血液の透析及
び濾過を兼用できる人工腎臓、(4) へ・臂すンポ
ングを必要としない人工腎臓。(1) An artificial kidney that has water removal speed close to that of a biological kidney, (2) An artificial kidney that does not require a blood pump, (3) An artificial kidney that can perform both dialysis and filtration of blood, and (4) An artificial kidney that can be used for both dialysis and filtration. Artificial kidney without.
先ず第1K生体腎の除水ス♂−ドに近い人工腎臓である
が、一般に生体腎が1日に除水即ち排尿する量は、生体
の状況、摂取水分量、体重、年令等によって異表るが、
約1.5L〜2.5t。First of all, although the artificial kidney is similar to the water removal system of the 1st K biological kidney, the amount of water removed, or urinated, by a biological kidney in a day varies depending on the biological condition, amount of water intake, body weight, age, etc. It appears, but
Approximately 1.5L to 2.5t.
平均すれば約2tであり、1時間当りにすると約80d
である。本発明による人工腎臓の除水能力はこの生体腎
の平均排尿速度でよい。第2に血液ポンプを必要としな
い人工腎臓としては、動脈圧によりh流及び限外濾過圧
力を確保し得る人工腎臓であり、通常動脈圧が70〜1
50■Hfであるので、血液浄化を行なう人工腎臓の圧
力損失が小さい程良< 、10mHP以下位が望ましい
。On average, it is about 2t, which is about 80d per hour.
It is. The water removal capacity of the artificial kidney according to the present invention may be the average micturition rate of the living kidney. Second, as an artificial kidney that does not require a blood pump, it is an artificial kidney that can secure h flow and ultrafiltration pressure using arterial pressure, and arterial pressure is usually 70 to 1.
50 mHP, so the smaller the pressure loss of the artificial kidney for blood purification, the better, preferably 10 mHP or less.
第3に血液の透析及び−過を兼用できる本発明による人
工腎臓であるが、昼間は血液濾過により除水のみを行な
い、夜間就寝中には透析液を用いる血液透析により、電
解質の調整、酸塩基平衡の調整を主として行なうが、−
この際、除水も同時に行なってもよい。第4にヘパリン
ポンプを必要としない人工腎臓については、噴霧器等圧
よりへp4リンを霧状にして患者の吸気にて肺臓に吸引
させ、肺臓のマスト・セル(肥満細胞)に吸収させれば
、持続的に血液中に徐放され、抗凝血作用を発揮するこ
と、を見い出し、ヘノ臂すンポングを不要とした。Third, the artificial kidney according to the present invention is capable of both dialysis and filtration of blood, but during the day it only removes water through hemofiltration, and at night while sleeping, it performs hemodialysis using dialysate to adjust electrolytes and remove acid. It mainly adjusts the base balance, but -
At this time, water removal may also be performed at the same time. Fourthly, for an artificial kidney that does not require a heparin pump, p4 phosphorus can be atomized using an isobaric nebulizer, inhaled into the lungs by the patient's inhalation, and absorbed into the mast cells of the lungs. It was discovered that the drug is continuously and slowly released into the blood and exerts an anticoagulant effect, thereby eliminating the need for knee-sucking.
以上の4項目により構成した本発明の装着型人工腎臓は
、昼間の日常生活に支障をきたさない極めて小型化且つ
簡略化し、しかも水分除去、老廃物除去、電解質の調整
、酸塩基平衡の調整)等の人工腎臓としての十分な機能
を発揮で自るが、本発明の装着型人工腎臓の一実施例に
ついて、図面に基づき更に詳しく説明する。The wearable artificial kidney of the present invention, which is constructed according to the above four items, is extremely miniaturized and simplified so that it does not interfere with daytime daily life, and is also capable of removing water, removing waste products, adjusting electrolytes, and adjusting acid-base balance. An embodiment of the wearable artificial kidney of the present invention will be described in more detail with reference to the drawings.
#I1図及び第2図は、本発明による装着型人工腎臓の
装着例を示すが、第1図は日常活動を行なう昼間に血液
濾過を行なう場合、第2図は夜間等就寝中に血液透析を
行なう場合の装着例を示す。先ず、第1図に従い説明す
ると、人工腎臓(1)はへマドクリット値約11血流量
100d / min下で限外濾過率が約10〜加−/
箇Hf 。#I1 and Figure 2 show examples of how the wearable artificial kidney according to the present invention is installed. An example of installation is shown below. First, to explain according to FIG. 1, the artificial kidney (1) has an ultrafiltration rate of about 10 to 10% at a hematocrit value of about 11 and a blood flow of 100 d/min.
Hf.
HR、l/、望むらくは約20〜25 yet/ws
Hl、 HR、M”程度を出せる膜素材であればよく、
例えばポリスルホン、プリエーテルスルホン、?リメチ
ルメタアクリレート、ポリアクリルニトリル、Iリカー
がネート、エチレンビニルアセテート、セルロースアセ
テート等高分子膜素材がよいが、更に望ましくはポリス
ルホン或いはセルロースアセテート系膜素材は、本発明
者等が行なった実験の結果では、血液中蛋白成分や血小
板の付着が他の膜素材に比し少く、本発明の意図する装
着型人工腎臓には適する。また膜の形状については、中
空糸型或いは平板層のどちらでもよいが、後述する第2
図に示す血液透析をも行なう必要上、膜の断面構造上か
らは、均層膜或いは膜の両サイド、即ち血液側及び透析
液側の両面にスキン層を有する膜が望ましい。膜面積は
患者の平均活動時間を16時間、就寝時間を8時間とし
、1日の除水量を21.膜にかかる平均血圧が70〜1
50■Hfの場合、前述の限外p通事が20〜2’5W
11/慎HP、HRlIJ” の膜素材からなる人工腎
#(1)では、約0.02〜0.06M”でよく、非常
に小型化された人工腎臓が可能である事は明らかである
。HR, l/ws, preferably about 20-25 yet/ws
Any membrane material that can produce Hl, HR, M” is fine.
For example, polysulfone, preethersulfone? Preferred are polymeric membrane materials such as trimethyl methacrylate, polyacrylonitrile, I-liquorate, ethylene vinyl acetate, and cellulose acetate, but more preferably polysulfone or cellulose acetate membrane materials are based on the results of experiments conducted by the present inventors. The results show that the adhesion of blood protein components and platelets is lower than that of other membrane materials, making it suitable for the wearable artificial kidney intended by the present invention. Regarding the shape of the membrane, either a hollow fiber type or a flat plate layer may be used.
Since it is necessary to perform the hemodialysis shown in the figure, and from the viewpoint of the cross-sectional structure of the membrane, a homogeneous membrane or a membrane having skin layers on both sides of the membrane, that is, on both the blood side and the dialysate side, is desirable. The membrane area is calculated based on the patient's average active time of 16 hours and bedtime of 8 hours, and the amount of water removed per day is 21. The average blood pressure across the membrane is 70-1
In the case of 50■Hf, the above-mentioned limit p passage is 20~2'5W
11/Shin HP, HRlIJ", it is clear that a membrane material of approximately 0.02 to 0.06 M" is sufficient, and that a very miniaturized artificial kidney is possible.
この人工腎臓(1)はバンド等により胴、腕、足等に固
定するが、該人工腎臓(1)への血液の供給は、血流量
が50〜250 d / min 、好ましくは100
〜150 d / winとれ、装着位置に近い動静脈
が望ましく、動脈からシャントを介して体外へ取り出さ
れた血液は、血液入口側連結チューブ(2)を通り人工
腎臓(1)内に流入し、血圧により血液−過された後、
血液出口側連結チューブ(3)を通り、クヤントを介し
て静脈内圧戻される。一方血液濾過により発生した廃棄
すべtkF液はろ液ボート(8)に接続した排出チュー
ブ(4)を通り、身体の適切な位置にバンド等で固定し
た濾過バッグ(5)に貯溜する。血液入口側連結チュー
ブ(2)及び血液出口側連結チューブの材質は、シリコ
ーン樹脂、Iリフレタン樹脂、弗素樹脂、Iり塩化ビニ
ル樹脂等から成るが、長期に亘る抗血栓性の面から、シ
リコーン樹脂或いは?リフレタン樹脂が望ましい。排出
チューブ(4)は、シリコーン樹脂、ポリウレタン樹脂
、テリ塩化ビニル樹脂、天然ゴム、合成ゴム等からなる
。P液バツク(5)は、形状的には袋状或いは&)ル形
状、いずれでもよいが、身体への装着の容易さ、廃棄の
答易さ等から、軟質塩化ビニル樹脂、エチレン共重合体
樹脂、ポリエチレン樹脂等からなるフレキシブルな袋状
のもの、或いは偏平の&)形状のものが好ましく、F液
が一杯貯れば、新しいF液バッグ等と交換する。キャラ
7’ (6)は、第2図で後述する血液透析時に用いる
透析液出口側ポート(7)Kかぶせてあり、血液V適時
にはF液の漏れ防止用の密栓である。This artificial kidney (1) is fixed to the torso, arms, legs, etc. with a band or the like, and blood is supplied to the artificial kidney (1) at a blood flow rate of 50 to 250 d/min, preferably 100 d/min.
~150 d/win, preferably an artery and vein close to the installation position, blood taken out of the body from the artery via the shunt flows into the artificial kidney (1) through the blood inlet side connection tube (2), After the blood is filtered by blood pressure,
The blood passes through the outlet connecting tube (3) and is returned to intravenous pressure via the quinant. On the other hand, the waste TKF fluid generated by blood filtration passes through a discharge tube (4) connected to a filtrate boat (8) and is stored in a filtration bag (5) fixed at an appropriate position on the body with a band or the like. The materials of the blood inlet side connecting tube (2) and the blood outlet side connecting tube are silicone resin, I-refrethane resin, fluororesin, I-resin vinyl chloride resin, etc. However, from the viewpoint of long-term antithrombotic properties, silicone resin is used. Or? Refletane resin is preferred. The discharge tube (4) is made of silicone resin, polyurethane resin, polyvinyl chloride resin, natural rubber, synthetic rubber, or the like. The P-liquid bag (5) may have either a bag-like shape or a bag-like shape, but it may be made of soft vinyl chloride resin or ethylene copolymer for ease of attachment to the body and ease of disposal. A flexible bag-like bag made of resin, polyethylene resin, etc., or a flat &)-shaped bag is preferable, and when the F liquid is full, it is replaced with a new F liquid bag. The character 7' (6) is covered with a dialysate outlet port (7)K used during hemodialysis, which will be described later in FIG.
次に第2図に従い、夜間等就寝中に血液透析を行う場合
について説明する。Next, referring to FIG. 2, a case in which hemodialysis is performed during sleep, such as at night, will be described.
人工腎臓(1)、血液入口側連結チューブ(2)、血液
出口側連結チューブ(3)は、前述した血液濾過に使っ
たものをそのまま用いる。即ち血液側の流路系について
は一切変更しないで、容易に血液透析に切り替え可能な
点も、本発明の装着型人工腎臓の大きな特長の1つであ
る。前述の血液濾過においてF液の出口として設けたF
液ポート(8)に透析液流入用チューブ(9)を、また
前述の透析液出口側ポート(7)にかぶせてあったキャ
ップ(6)をとりはずし、咳透析液出口側ホー)(7)
K透析液吸引用チューブ(10)の一端を接続し、他端
に除圧ポンf (13)を接続する。透析液は、予め所
用量を透析液タンク(11)に貯溜しておく。該透析液
タンク(11)と透析液流入用チューブ(9)の間に、
ニードルパルプ等の陰圧バルブ(12)を設ける。この
透析液側の回路構成により除圧ポンプ(13)の吸引力
により、透析液は透析液タンク(11)から陽圧パルプ
(12)、透析液流入用チューブ(9)、F液ボート(
8)を介して、人工腎臓(1)内の前述した血液濾過の
際のF液の通路に入り、前述の膜を介して血液中の電解
質バランスの調整、酸塩基平衡の調整を行なうと共に老
廃物及び水分の除去をも行ないながら人工腎臓(1)の
透析液出口側ポート(7)、透析液吸引用チューブ(1
0)、除圧ポンプ(13)を経て下水等にドレーンされ
る。この操作の際、除圧バルブ(12)を絞り、人工腎
臓(1)内の透析液側に除圧を掛けることにより、血液
中の水分の除去速度を早めることが可能である。The artificial kidney (1), the blood inlet side connecting tube (2), and the blood outlet side connecting tube (3) are the same as those used in the blood filtration described above. That is, one of the major features of the wearable artificial kidney of the present invention is that it can be easily switched to hemodialysis without changing the flow path system on the blood side. F provided as an outlet for the F solution in the aforementioned blood filtration.
Remove the dialysate inflow tube (9) from the dialysate port (8) and the cap (6) that was placed over the dialysate outlet port (7).
K. Connect one end of the dialysate suction tube (10), and connect the other end to the depressurization pump f (13). A required amount of dialysate is stored in a dialysate tank (11) in advance. Between the dialysate tank (11) and the dialysate inflow tube (9),
A negative pressure valve (12) such as needle pulp is provided. With this circuit configuration on the dialysate side, the dialysate is transferred from the dialysate tank (11) to the positive pressure pulp (12), the dialysate inflow tube (9), and the F liquid boat (
8), it enters the passage of the F fluid during the blood filtration described above in the artificial kidney (1), and adjusts the electrolyte balance and acid-base balance in the blood through the membrane described above, as well as removing waste. While removing substances and water, the dialysate outlet port (7) of the artificial kidney (1) and dialysate suction tube (1) are removed.
0), and is drained to sewage etc. via a pressure relief pump (13). During this operation, it is possible to speed up the removal of water from the blood by restricting the pressure relief valve (12) and applying pressure relief to the dialysate side within the artificial kidney (1).
第1図及び第2図によ妙血液濾過から血液透析に切り替
える方法を述べたが、全く逆の手順に従えば血液透析か
ら血液濾過に切や替えられる事は明らかであり、本発明
の装着型人工腎臓は性能が保持される限り、この切り替
えを繰9返す事により、血液浄化を行なう事が大きな特
徴である。Although the method of switching from hemofiltration to hemodialysis has been described in FIGS. 1 and 2, it is clear that it is possible to switch from hemodialysis to hemofiltration by following the completely reverse procedure. A major feature of the type artificial kidney is that it purifies blood by repeating this switching nine times as long as its performance is maintained.
更に本発明者等は、前記したヘパリンの投与法、即ち肺
臓のマスト・、鴫ルに吸収させ九へバリンの血液中への
徐放性を見い出し、へ/9リン注入ポンプを使うことな
く抗凝血性を持続させる事に成功した故、本発明による
装着型人工腎臓の臨床的優位性、並びに社会的優位性を
向上し得たものである。Furthermore, the present inventors have discovered a method of administering heparin as described above, that is, absorption into the mast cells of the lungs, and sustained release of heparin into the blood, thereby achieving anti-heparin therapy without using a heparin infusion pump. Since we succeeded in sustaining blood coagulation, we were able to improve the clinical and social advantages of the wearable artificial kidney according to the present invention.
以上、詳述した如く、本発明による装着型人工腎臓は慢
性腎不全等の腎疾患患者の念願である社会復帰に大いに
貢献する極めて有用なる発明である。As described above in detail, the wearable artificial kidney according to the present invention is an extremely useful invention that greatly contributes to the rehabilitation of patients with renal diseases such as chronic renal failure into society, which is the long-awaited goal of patients with renal diseases such as chronic renal failure.
図面は本発明の一実施例であり、第1図は本発明の人工
腎臓を装着し血液濾過を行なう際の概略図、第2図は本
発明の人工腎臓を装着し、血液透析を行なう際め概略図
である。
特許出願人 住友ベークライト株式会社:、1The drawings show one embodiment of the present invention; Fig. 1 is a schematic diagram when the artificial kidney of the present invention is installed and blood filtration is performed, and Fig. 2 is a schematic diagram when the artificial kidney of the present invention is installed and hemodialysis is performed. FIG. Patent applicant Sumitomo Bakelite Co., Ltd.: 1
Claims (1)
させることKより、抗凝血性を持続させ得る血液条件下
において、血液−過と血液透析との両機能を有する膜で
構成された人工腎臓に1血液濾過時はろ液貯溜用のろ液
バッグ等を接続し、且つ血液透析時は、前記人工腎臓に
接続した前記戸液バッグ等を除去し、前記人工腎臓内の
r液の通路に透析液を流し得る構造を有する事を特徴と
する装着型人工腎臓。By absorbing heparin into the mast cells of the lungs and gradually releasing it under blood pressure, an artificial membrane composed of a membrane that has both blood flow and hemodialysis functions under blood conditions that can maintain anticoagulant properties. During hemofiltration, a filtrate bag for storing filtrate is connected to the kidney, and during hemodialysis, the liquid bag connected to the artificial kidney is removed and the r-fluid passage in the artificial kidney is connected. A wearable artificial kidney characterized by having a structure through which dialysate can flow.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56173716A JPS5875558A (en) | 1981-10-31 | 1981-10-31 | Mountable artificial kidney |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56173716A JPS5875558A (en) | 1981-10-31 | 1981-10-31 | Mountable artificial kidney |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5875558A true JPS5875558A (en) | 1983-05-07 |
Family
ID=15965806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56173716A Pending JPS5875558A (en) | 1981-10-31 | 1981-10-31 | Mountable artificial kidney |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5875558A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525878A (en) * | 2002-05-17 | 2005-09-02 | ヘマプール アーベー | Apparatus and system for filtering blood |
US10568781B2 (en) | 2005-02-17 | 2020-02-25 | The Procter & Gamble Company | Sanitary napkins capable of taking complex three-dimensional shape in use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4911037A (en) * | 1972-04-07 | 1974-01-31 | ||
JPS589148B2 (en) * | 1980-01-11 | 1983-02-19 | 日立化成工業株式会社 | Electroless plating device |
-
1981
- 1981-10-31 JP JP56173716A patent/JPS5875558A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4911037A (en) * | 1972-04-07 | 1974-01-31 | ||
JPS589148B2 (en) * | 1980-01-11 | 1983-02-19 | 日立化成工業株式会社 | Electroless plating device |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525878A (en) * | 2002-05-17 | 2005-09-02 | ヘマプール アーベー | Apparatus and system for filtering blood |
JP4727983B2 (en) * | 2002-05-17 | 2011-07-20 | ガンブロ ルンディア アー・ベー | Apparatus and system for filtering blood |
US8153008B2 (en) | 2002-05-17 | 2012-04-10 | Gambro Lundia Ab | Device and method for filtering blood |
US8617392B2 (en) | 2002-05-17 | 2013-12-31 | Gambro Lundia Ab | Device and system for filtering blood |
US8852433B2 (en) | 2002-05-17 | 2014-10-07 | Gambro Lundia Ab | Device and system for filtering blood |
US10568781B2 (en) | 2005-02-17 | 2020-02-25 | The Procter & Gamble Company | Sanitary napkins capable of taking complex three-dimensional shape in use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7597677B2 (en) | Wearable ultrafiltration device | |
ES2548562T3 (en) | Device for fluid withdrawal from a peripheral vein in case of heart failure | |
US5151082A (en) | Apparatus and method for kidney dialysis using plasma in lieu of blood | |
JP4557484B2 (en) | Method and apparatus for monitoring and controlling peritoneal dialysis therapy | |
US5980478A (en) | Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration | |
US5902336A (en) | Implantable device and method for removing fluids from the blood of a patient method for implanting such a device and method for treating a patient experiencing renal failure | |
CN209900240U (en) | Wearable filtering artificial kidney device | |
US20220241477A1 (en) | Portable continuous renal replacement therapy system and methods | |
JPS5875558A (en) | Mountable artificial kidney | |
Vanholder et al. | Single needle haemodialysis | |
Handley et al. | Intravenous catheter for intracorporeal plasma filtration | |
Rajhans et al. | Design of wearable dialysis unit | |
Bem et al. | Ammonium removal with a novel zirconium silicate | |
Roberts et al. | Wearable Artificial Kidneys: A Historical Perspective | |
Aboras et al. | Continuous convective renal replacement (CCRR) system: A new modality of wearable artificial kidney | |
Kumar et al. | Extended daily dialysis (EDD) rapidly reduces serum phosphate levels in intensive care unit (ICU) patients with acute renal failure (ARF) | |
Ronco et al. | Machines for continuous renal replacement therapies | |
Handley Jr et al. | An experimental temporary vascular access catheter for intracorporeal plasma separation | |
Liao et al. | CHARACTERIZATION OF DIALYZER MEMBRANE TRANSPORT WITH A NEW EXPERIMENTAL SYSTEM | |
JP2003220133A (en) | Dialyzer and hollow fiber used for the same | |
Krivitski et al. | K/DOQI ACCESS FLOW (AF) THRESHOLD GUIDELINES-IS THERE A THEORETICAL BASIS? | |
Shulman et al. | PRESERVING CENTRAL BLOOD VOLUME [CBV]: CHANGES IN BODY FLUID COMPARTMENTS DURING HEMODIALYSIS | |
Steuer et al. | NONINVASIVE CONTINUOUS UREA REDUCTION RATIO & UREA CLEARANCE DETERMINATION: A NEW PHOTOMETRIC TECHNIQUE | |
BIASIOLI et al. | CHRONIC VITAMINIC SUPPLEMENTATION OF HEMODIALYSIS POPULATION | |
Siami et al. | DUAL CRYOFILTRATION APHERESIS TREATMENT OF PATIENTS WITH VERY HIGH CRYOGLOBULINS |